BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25158280)

  • 1. MEIS1 functions as a potential AR negative regulator.
    Cui L; Li M; Feng F; Yang Y; Hang X; Cui J; Gao J
    Exp Cell Res; 2014 Oct; 328(1):58-68. PubMed ID: 25158280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LINE-1 ORF-1p functions as a novel androgen receptor co-activator and promotes the growth of human prostatic carcinoma cells.
    Lu Y; Feng F; Yang Y; Gao X; Cui J; Zhang C; Zhang F; Xu Z; Qv J; Wang C; Zeng Z; Zhu Y; Yang Y
    Cell Signal; 2013 Feb; 25(2):479-89. PubMed ID: 23153584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity.
    Whitlock NC; Trostel SY; Wilkinson S; Terrigino NT; Hennigan ST; Lake R; Carrabba NV; Atway R; Walton ED; Gryder BE; Capaldo BJ; Ye H; Sowalsky AG
    Oncogene; 2020 Aug; 39(34):5663-5674. PubMed ID: 32681068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of androgen receptor-mediated transcription by RPB5 binding protein URI/RMP.
    Mita P; Savas JN; Djouder N; Yates JR; Ha S; Ruoff R; Schafler ED; Nwachukwu JC; Tanese N; Cowan NJ; Zavadil J; Garabedian MJ; Logan SK
    Mol Cell Biol; 2011 Sep; 31(17):3639-52. PubMed ID: 21730289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
    Li L; Xie H; Liang L; Gao Y; Zhang D; Fang L; Lee SO; Luo J; Chen X; Wang X; Chang LS; Yeh S; Wang Y; He D; Chang C
    Carcinogenesis; 2013 Feb; 34(2):257-67. PubMed ID: 23104178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification and identification of a novel complex which is involved in androgen receptor-dependent transcription.
    Hosohata K; Li P; Hosohata Y; Qin J; Roeder RG; Wang Z
    Mol Cell Biol; 2003 Oct; 23(19):7019-29. PubMed ID: 12972618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
    Yoon HG; Wong J
    Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor PAX6 functions as androgen receptor co-repressor to inhibit prostate cancer growth.
    Shyr CR; Tsai MY; Yeh S; Kang HY; Chang YC; Wong PL; Huang CC; Huang KE; Chang C
    Prostate; 2010 Feb; 70(2):190-9. PubMed ID: 19790232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
    Tsui KH; Chang YL; Feng TH; Hou CP; Lin YH; Yang PS; Lee BW; Juang HH
    Prostate; 2018 Mar; 78(4):242-249. PubMed ID: 29164633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
    Axlund SD; Lambert JR; Nordeen SK
    Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.
    Li N; Chen M; Truong S; Yan C; Buttyan R
    Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.
    Cinar B; Yeung F; Konaka H; Mayo MW; Freeman MR; Zhau HE; Chung LW
    Biochem J; 2004 Apr; 379(Pt 2):421-31. PubMed ID: 14715080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia increases androgen receptor activity in prostate cancer cells.
    Park SY; Kim YJ; Gao AC; Mohler JL; Onate SA; Hidalgo AA; Ip C; Park EM; Yoon SY; Park YM
    Cancer Res; 2006 May; 66(10):5121-9. PubMed ID: 16707435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer.
    McClurg UL; Harle VJ; Nabbi A; Batalha-Pereira A; Walker S; Coffey K; Gaughan L; McCracken SR; Robson CN
    Oncotarget; 2015 Nov; 6(35):37724-36. PubMed ID: 26462181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
    Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
    Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
    Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
    J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3.
    Argiropoulos B; Yung E; Xiang P; Lo CY; Kuchenbauer F; Palmqvist L; Reindl C; Heuser M; Sekulovic S; Rosten P; Muranyi A; Goh SL; Featherstone M; Humphries RK
    Blood; 2010 May; 115(20):4071-82. PubMed ID: 20237320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
    Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
    Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.